Pre-made Racotumomab benchmark antibody ( Whole mAb, anti-Idiotope of anti-NeuGc-ganliosides therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Racotumomab biosimilar, Whole Mab: Anti-Idiotope of Anti-NeuGc-ganliosides therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by Recombio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient’s immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.